23andMe And Nightingale Health Announce Strategic Collaboration To Pilot Blood Biomarker Panel
June 28 2024 - 6:00AM
23andMe Holding Co. (Nasdaq: ME), a leading preventive health and
therapeutics company, and Nightingale Health Plc, a pioneer in
biomarker testing and risk prediction, today announced a strategic
collaboration to pilot Nightingale Health’s clinically-validated
and cost-effective blood metabolomics panel with a cohort of
23andMe members.
Nightingale’s Remote Health Check accurately measures dozens of
biomarkers from a single blood sample, including cholesterols,
apolipoproteins and fatty acids like omega-3. Many of these blood
biomarkers have established clinical relationships to disease and
can help guide important lifestyle interventions – such as diet and
exercise. This pilot marks an important milestone in making blood
testing more efficient and accessible.
23andMe currently offers its annual members the option for blood
testing and provides interactive tools like HealthTracks, a feature
that incorporates customer lifestyle choices into calculating a
lifetime risk of disease. Blood biomarkers may improve the accuracy
of these predictions and provide more direct insight into the kinds
of interventions that may be most impactful to a customer’s
health.
As part of the pilot, 23andMe will offer up to 5,000 23andMe+
Premium and Total Health members the opportunity to receive blood
testing through Nightingale’s Remote Health Check at no cost to
them. The pilot will evaluate customer feedback around blood
testing, at-home sample collection, and the utility of the data
when coupled with 23andMe’s established personal genetics
products.
23andMe and Nightingale Health have a shared vision to help
individuals identify health risks and prevent disease through
proactive testing, treatment, coaching and behavior change.
Together, the companies’ technologies allow for a more
comprehensive assessment of a customer’s health and continuous
tracking of progress toward their goals.
“We are truly impressed with Nightingale Health’s capabilities
in blood biomarker testing. Their work with public biobank projects
and resulting publications have previewed the exciting potential
for metabolomics in prediction. We believe this collaboration will
ultimately help our customers lead longer, healthier lives,” said
Anne Wojcicki, CEO and Co-Founder of 23andMe. “We are enthusiastic
about long-term opportunities that combine the power of our
technologies.”
“This collaboration enables a globally unique feature set for
23andMe’s consumer health services. Together, we can help customers
track and improve their health with regular blood testing using
Nightingale Health’s technology,” said Teemu Suna, CEO and Founder
of Nightingale Health. “This marks an important step in the
execution of Nightingale Health’s strategy, as it announces an
important partnership providing access to the consumer health
market.”
About 23andMe23andMe is a genetics-led consumer
healthcare and therapeutics company empowering a healthier future.
For more information, please visit www.23andme.com.
Forward-Looking StatementsThis press release
contains forward-looking statements within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended, including. All
statements, other than statements of historical fact, included or
incorporated in this press release are forward-looking statements.
The words "believes," "anticipates," "estimates," "plans,"
"expects," "intends," "may," "could," "should," "potential,"
"likely," "projects," “predicts,” "continue," "will," “schedule,”
and "would" or, in each case, their negative or other variations or
comparable terminology, are intended to identify forward-looking
statements, although not all forward-looking statements contain
these identifying words. These forward-looking statements are
predictions based on 23andMe’s current expectations and projections
about future events and various assumptions. 23andMe cannot
guarantee that it will actually achieve the plans, intentions, or
expectations disclosed in its forward-looking statements and you
should not place undue reliance on 23andMe’s forward-looking
statements. These forward-looking statements involve a number of
risks, uncertainties (many of which are beyond the control of
23andMe), or other assumptions that may cause actual results or
performance to differ materially from those expressed or implied by
these forward-looking statements. The forward-looking statements
contained herein are also subject generally to other risks and
uncertainties that are described from time to time in the Company’s
filings with the Securities and Exchange Commission, including
under Item 1A, “Risk Factors” in the Company’s most recent Annual
Report on Form 10-K, as filed with the Securities and Exchange
Commission, and as revised and updated by our Quarterly Reports on
Form 10-Q and Current Reports on Form 8-K. The statements made
herein are made as of the date of this press release and, except as
may be required by law, 23andMe undertakes no obligation to update
them, whether as a result of new information, developments, or
otherwise.
For further information, please
contact:23andMepress@23andme.cominvestors@23andme.com
23andMe (NASDAQ:ME)
Historical Stock Chart
From Jun 2024 to Jul 2024
23andMe (NASDAQ:ME)
Historical Stock Chart
From Jul 2023 to Jul 2024